Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LJP 1082

Drug Profile

LJP 1082

Alternative Names: LJP-1082

Latest Information Update: 10 May 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator La Jolla Pharmaceutical Company
  • Class Anticoagulants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Antiphospholipid syndrome; Thrombosis

Most Recent Events

  • 30 May 2006 Suspended - Phase-I for Antiphospholipid syndrome in USA (unspecified route)
  • 30 May 2006 Suspended - Phase-I for Thrombosis in USA (unspecified route)
  • 17 Nov 2003 Data presented at the 67th Annual Scientific Meeing of the American College of Rheumatology and the 38th Annual Meeting Association of Rheumatology Health Professionals (ACR/ARHP-2003) have been added to the adverse events and pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top